The European Commission approved Rydapt (midostaurin) for use in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adults with newly diagnosed acute myeloid leukemia who are FLT3 mutation-positive.
In 1996, Lei Zheng, a graduate of Peking Union Medical College, enrolled in the doctorate program at what was then known as the Cancer Therapy & Research Center in San Antonio.
